FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa - Quiz - MDSpire

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

The optimal exercise for improving inhibitory control in children and adolescents with NDDs: a systematic review and network meta-analysis

Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.